,
a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting. DCVAC/OvCa is being developed as a first line treatment in adults with ovarian cancer.
The data demonstrate signs of efficacy and safety of
DCVAC/OvCa combined with chemotherapy in patients with newly diagnosed epithelial ovarian carcinoma and
provide strong rationale for potential study in larger clinical trials.
Data highlights from the poster entitled, “Dendritic cell vaccine (DCVAC) combined with chemotherapy in patients with newly diagnosed epithelial ovarian carcinoma after primary debulking surgery: Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial” include:
Share this article
Share this article
ARLINGTON, Va., June 4, 2021 /PRNewswire/ Although cancer patients have a disproportionately higher COVID-19 mortality rate, they have nuanced vaccine attitudes. While a majority of patients expressed interest in vaccination, feelings about what vaccination can accomplish mirrored the nation s political divide. Concurrently, cancer patients report adverse events comparable with the general population. These results are from studies conducted by
Inspire, the vital health community for millions of patients and caregivers, and COSMO, the Collaboration for Outcomes using Social Media in Oncology, and are being presented June 4-8 at the American Society of Clinical Oncology® (ASCO) conference.
Sotio
SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting
SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting
PRAGUE, Czech Republic, June 04, 2021 (GLOBE NEWSWIRE)
,
a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting. DCVAC/OvCa is being developed as a first line treatment in adults with ovarian cancer.